PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company focused on developing cell-based therapies for chronic kidney disease, principally its REACT program aimed at slowing or reversing the progression of renal dysfunction. The company entered the public markets through a SPAC merger, with the business combination closing in 2022 following the blank-check vehicle's initial public offering in 2021. Operating within the healthcare and biotechnology sector, ProKidney filed an 8-K current report with the SEC on May 31, 2024, representing an ongoing material disclosure obligation as a post-merger Nasdaq-listed company. Investors and analysts tracking ProKidney and the broader SPAC universe can sign up at SpacDesk for full filing history, sponsor profiles, and real-time deal analytics.